

Disorder	Causative Gene or Region (OMIM#)
<b>Imprinting and Trinucleotide Repeat Disorders</b>	
Angelman syndrome (AS)	15q11.2-q13 ( <i>SNRPN</i> promoter, <i>SNURF</i> ) (105830)
Beckwith-Wiedemann syndrome (BWS)	11p15 (IC1 and IC2) (130650)
Diabetes mellitus, transient neonatal 1 (TNDM1)	6q24 ( <i>PLAG1</i> ) (601410)
Fragile X syndrome (FXS)	<i>FMR1</i> promoter (300624)
Kagami-Ogata syndrome	14q32 ( <i>MEG3</i> promoter) (608149)
Mulchandani-Bhoj-Conlin syndrome (MBCS)	20q11-q13 ( <i>GNAS</i> ) (617352)
Prader-Willi syndrome (PWS)	15q11.2 ( <i>SNRPN</i> promoter, <i>SNURF</i> ) (176270)
Pseudohypoparathyroidism, Type IA, IB (PHP1A, PHP1B)	20q13.32 ( <i>GNAS</i> ) (139320/603233)
Silver-Russel syndrome 1 (SRS1)	11p15 (IC1 and IC2) (180860)
Silver-Russel syndrome 2 (SRS2)	7p13-q32 (618905)
Temple syndrome	14q32 ( <i>MEG3</i> promoter) (616222)
<b>Episignature Disorders</b>	
Alpha-thalassemia/Impaired intellectual development syndrome, X-linked <sup>1</sup>	<i>ATRX</i> (301040)
Arboleda-Tham syndrome (ARTHS) <sup>2</sup>	<i>KAT6A</i> (616268)
ARID1A duplication-related syndrome <sup>2,3*</sup>	<i>ARID1A</i> (603024)
BAFopathies: Coffin-Siris 1-4 (CSS1, CSS2, CSS3, CSS4) & Nicolaides-Baraitser (NCBRS) syndromes <sup>4</sup>	<i>ARID1B</i> , <i>ARID1A</i> , <i>SMARCB1</i> , <i>SMARCA4</i> , <i>SMARCA2</i> (135900, 614607, 614608, 614609, 601358)
BAFopathies: Coffin-Siris syndrome 1 and 2 (CSS1, CSS2) <sup>5</sup>	<i>ARID1B</i> , <i>ARID1A</i> (135900, 614607)
Beck-Fahrner syndrome (BEFAHRS) <sup>6,7</sup>	<i>TET3</i> (618798)
Blepharophimosis-impaired intellectual development syndrome (BIS)	<i>SMARCA2</i> (619293)
Börjeson-Forsssman-Lehmann syndrome (BFLS) <sup>1,2,8</sup>	<i>PHF6</i> (301900)
Branchial arch abnormalities, choanal atresia, athelia, hearing loss, and hypothyroidism syndrome (BCAHH) <sup>2,9*</sup>	<i>KMT2D</i> (620186)
Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant (ADCADN) <sup>2</sup>	<i>DNMT1</i> (604121)
CHARGE syndrome	<i>CHD7</i> (214800)
Chr1p36 deletion syndrome <sup>2,10</sup>	Chr1p36 deletion (607872)
Chromosome 19p13.13 Deletion Syndrome <sup>11*</sup>	Chr19p13.13del (613638)
Chromosome Xp11.22 duplication syndrome <sup>1,2,12*</sup>	ChrXp11.22 duplication (300705)
Chung-Jansen syndrome, White-Kernohan syndrome and Börjeson-Forsssman-Lehmann syndrome*	<i>PHIP</i> , <i>DDB1</i> , <i>PHF6</i> (617991, 619426, 301900)
Chung-Jansen syndrome <sup>2,8</sup> Error! Bookmark not defined.*	<i>PHIP</i> (617991)
Clark-Baraitser syndrome*	<i>TRIP12</i> (617752)
Coffin-Siris syndrome-1 (CSS1) <sup>2,13</sup>	<i>ARID1B</i> (135900)
Coffin-Siris syndrome-2 (CSS2) <sup>2,13</sup>	<i>ARID1A</i> (614607)
Coffin-Siris syndrome-3 (CSS3) <sup>2,13</sup>	<i>SMARCB1</i> (614608)
Coffin-Siris syndrome-4 (CSS4) <sup>2,13</sup>	<i>SMARCA4</i> (614609)
Coffin-Siris syndrome-4 (CSS4) <sup>2,13,14</sup>	<i>SMARCA4</i> c.2656 (614609)
Coffin-Siris syndrome-6 (CSS6)*	<i>ARID2</i> (617808)
Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD) <sup>2</sup>	<i>CDK13</i> , <i>CCNK</i> (617360)

Cornelia de Lange syndromes 1-4 (CDLS1, CDLS2, CDLS3, CDLS4) <sup>15</sup>	<i>NIPBL, SMC1A, SMC3, RAD21</i> (122470, 300590, 610759, 614701)
DEGCAGS syndrome <sup>16*</sup>	<i>ZNF699</i> (619488)
Desanto-Shinawi syndrome (DESSH) <sup>†</sup>	<i>WAC</i> (616708)
Developmental and epileptic encephalopathy 54 (DEE54)*	<i>HNRNPU</i> (617391)
Developmental and epileptic encephalopathy 94 (DEE94)	<i>CHD2</i> (615369)
Developmental delay with or without dysmorphic facies and autism (DEDDFA) <sup>17†</sup>	<i>TRRAP</i> (618454)
Developmental delay with variable intellectual disability and dysmorphic facies*	<i>JARID2</i> (601594)
Diamond-Blackfan anemia 1 (DBA1) <sup>18†</sup>	<i>RPS19</i> (105650)
Diamond-Blackfan anemia 5 (DBA5) <sup>18†</sup>	<i>RPL35A</i> (612528)
Diets-Jongmans syndrome (DIJOS)*	<i>KDM3B</i> (618846)
Down syndrome	<i>Chr21 trisomy</i> (190685)
Dystonia 28, Childhood-onset (DYT28)	<i>KMT2B</i> (617284)
Fanconi Anemia (FANCA, FANCC, FANCD2, FANCG, FANCI, FANCL) <sup>16,19*</sup>	<i>FANCA, FANCC, FANCD2, FANCG, FANCI, FANCL</i> (227650, 613899, 613984, 602956, 611360, 608111)
Fetal valproate syndrome (FVS) <sup>20*</sup>	Not applicable (609442)
Floating-Harbor syndrome (FLHS)	<i>SRCAP</i> (136140)
Gabriele-de Vries syndrome (GADEVS) <sup>2</sup>	<i>YY1</i> (617557)
Genitopatellar syndrome (see also Ohdo syndrome) (GTPTS) <sup>2,21</sup>	<i>KAT6B</i> (606170)
Hao-Fountain syndrome (HAFOUS)*	<i>USP7</i> (616863)
Helsmoortel-van der Aa syndrome (HVDAS) <sup>22</sup>	<i>ADNP</i> (615873)
Hunter-McAlpine craniosynostosis syndrome <sup>23</sup>	<i>Chr5q35-qter duplication including NSD1</i> (601379)
Hypercholesterolemia, familial, 1 (FHCL1) <sup>24†</sup>	<i>LDLR</i> (143890)
Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase <sup>†</sup>	<i>AHCY</i> (613752)
Immunodeficiency-centromeric instability-facial anomalies syndromes 1-4 (ICF1, ICF2, ICF3, ICF4) <sup>2,25</sup>	<i>DNMT3B, CDCA7, ZBTB24, HELLS</i> (242860, 614069, 616910, 616911)
Intellectual developmental disorder with autism and macrocephaly (IDDAM) <sup>2</sup>	<i>CHD8</i> (615032)
Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities (IDDFBA) <sup>†</sup>	<i>FBXO11</i> (618089)
Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism (IDDMOH) <sup>2</sup>	<i>SOX11</i> (615866)
Intellectual developmental disorder with seizures and language delay (IDDSELD)	<i>SETD1B</i> (619000)
Intellectual Developmental Disorder with Speech Delay, Dysmorphic Facies, and T-cell abnormalities (IDDSFTA) <sup>2*</sup>	<i>BCL11B</i> (618092)
Intellectual developmental disorder, autosomal dominant 21 (MRD21)*	<i>CTCF</i> (615502)
Intellectual developmental disorder, autosomal dominant 23 (MRD23) <sup>2,26</sup>	<i>SETD5</i> (615761)
Intellectual developmental disorder, autosomal dominant 51 (MRD51) <sup>2,6</sup>	<i>KMT5B</i> (617788)
Intellectual developmental disorder, autosomal dominant 7 (MRD7)*	<i>DYRK1A</i> (600855)
Intellectual developmental disorder, X-linked 93 (XLID93) <sup>2,6</sup>	<i>BRWD3</i> (300659)

Intellectual developmental disorder, X-linked 97 (XLID97) <sup>2,27</sup>	<i>ZNF711</i> (300803)
Intellectual developmental disorder, X-linked 112 (XLID112) <sup>†</sup>	<i>ZMYM3</i> (301111)
Intellectual developmental disorder, X-linked syndromic, Nascimento-type (MRXSN) <sup>1,2</sup>	<i>UBE2A</i> (300860)
Intellectual developmental disorder, X-linked, syndromic, Armfield type (MRXSA) <sup>1,2</sup>	<i>FAM50A</i> (300261)
Intellectual developmental disorder, X-linked, syndromic, Claes-Jensen type (MRXSCJ) <sup>6,28</sup>	<i>KDM5C</i> (300534)
Intellectual developmental disorder, X-linked, syndromic, Snyder-Robinson type (MRXSSR) <sup>1,2</sup>	<i>SMS</i> (309583)
Kabuki syndrome 1 (KABUK1) <sup>29</sup>	<i>KMT2D</i> (147920)
Kabuki syndrome 1 and 2 (KABUK1, KABUK2)	<i>KMT2D, KDM6A</i> (147920, 300867)
Kabuki syndrome 2 (KABUK2) <sup>29</sup>	<i>KDM6A</i> (300867)
KBG Syndrome (KBGS) <sup>26</sup>	<i>ANKRD11</i> (148050)
KDM2B-related syndrome	<i>KDM2B</i> (609078)
Kleefstra syndrome 1 (KLEFS1)	<i>EHMT1</i> (610253)
Klinefelter Syndrome <sup>30</sup>	ChrX duplication; 47,XXY
KMT2C-related syndrome <sup>†</sup>	<i>KMT2C</i> (606833)
Koolen-De Vries syndrome (KDVS)	<i>KANSL1</i> (610443)
Luscan-Lumish syndrome (LLS)	<i>SETD2</i> (616831)
Menke-Hennekam syndrome 1 and 2 (MKHK1, MKHK2) <sup>31</sup>	<i>CREBBP, EP300</i> (618332, 618333)
Mowat-Wilson Syndrome (MOWS)*	<i>ZEB2</i> (235730)
MSL2 associated syndrome <sup>2*</sup>	<i>MSL2</i> (614802)
Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities (NECRC) <sup>†</sup>	<i>ZMYM2</i> (619522)
Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities (NEDFBA)*	<i>SRSF1</i> (620489)
Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language (NEDHSIL)*	<i>MEF2C</i> (613443)
Neuroocular syndrome <sup>2,32*</sup>	<i>PRR12</i> (619539)
Nicolaides-Baraitser syndrome (NCBRS) <sup>13</sup>	<i>SMARCA2</i> (601358)
NSD2 duplication syndrome <sup>33*</sup>	<i>NSD2</i> (602952)
Ohdo syndrome, SBBYSS variant (see also Genitopatellar syndrome) (SBBYSS) <sup>2,21</sup>	<i>KAT6B</i> (603736)
Phelan-McDermid syndrome (PHMDS) <sup>34</sup>	Chr22q13.3 deletion (606232)
PHF12-related syndrome <sup>†</sup>	<i>PHF12</i> (618645)
Pitt-Hopkins Syndrome (PTHS)*	<i>TCF4</i> (610954)
Potocki-Lupski syndrome (PTLS) <sup>35</sup>	Chr17p11.2 duplication (610883)
PRC2 Complex ((Weaver syndrome (WVS) and Cohen-Gibson syndrome (COGIS)) <sup>36</sup>	<i>EED, EZH2</i> (617561, 277590)
Rahman syndrome (RMNS)	<i>HIST1H1E</i> (617537)
Recurrent constellations of embryonic malformations <sup>37†</sup>	Not applicable
Renpenning syndrome (RENS1) <sup>1,2</sup>	<i>PQBP1</i> (309500)
Rubinstein-Taybi syndrome 1 (RSTS1) <sup>38</sup>	<i>CREBBP</i> (180849)
Rubinstein-Taybi syndrome 1 and 2 (RSTS1, RSTS2)	<i>CREBBP, EP300</i> (180849, 613684)

Rubinstein-Taybi syndrome 2 (RSTS2) <sup>38</sup>	<i>EP300</i> (613684)
Schuurs-Hoeijmakers syndrome (SHMS) <sup>†</sup>	<i>PACS1</i> (615009)
SETD1A-related syndrome <sup>†</sup>	<i>SETD1A</i> (611052)
Sifrim-Hitz-Weiss syndrome (SIHIWES)	<i>CHD4</i> (617159)
SLC32A1 related disorder <sup>2</sup>	<i>SLC32A1</i> (616440)
Smith-Magenis syndrome (SMS) <sup>39</sup>	Chr17p11.2 deletion (182290)
Sotos syndrome (SOTOS)	<i>NSD1</i> (117550)
Tatton-Brown-Rahman syndrome (TBRS) <sup>2</sup>	<i>DNMT3A</i> (615879)
Turner Syndrome*	Monosomy X
Velocardiofacial syndrome (VCFS) <sup>40</sup>	Chr22q11.2 deletion (192430)
White-Kernohan syndrome <sup>8*</sup>	<i>DDB1</i> (619426)
White-Sutton syndrome (WHSUS)	<i>POGZ</i> (616364)
Wieacker-Wolff Syndrome (WRWF) <sup>1,2</sup>	<i>ZC4H2</i> (314580)
Wiedemann-Steiner syndrome (WDSTS)	<i>KMT2A</i> (605130)
Williams-Beuren region duplication syndrome <sup>41</sup>	Chr7q11.23 duplication (609757)
Williams-Beuren syndrome (WBS) <sup>42</sup>	Chr7q11.23 deletion (194050)
Witteveen-Kolk syndrome (WITKOS) <sup>2</sup>	<i>SIN3A</i> (613406)
Wolf-Hirschhorn syndrome (WHS) & Rauch-Steindl Syndrome (RAUST) <sup>43</sup>	Chr4p16.13 deletion, <i>NSD2</i> (194190, 602952)

\*These disorders are new for V5 of EpiSign™.

†These epesignatures are available for EpiSign™ Single requests only.

<sup>1</sup> Defined with male cases only. Heterozygotes have been shown to not match the epesignature.

<sup>2</sup> Reduced sensitivity may be observed.

<sup>3</sup> The range of validated coordinates is 1p36.11(26,964,202-27,099,490). CNVs overlapping or expanding this region may also be detected.

<sup>4</sup> Patients with other BAFopathy genes may be detected, but not confirmed in our experiments.

<sup>5</sup> Only for variants near c.6200. No separate epesignature due small cohort size, however these samples cluster separately from other BAFopathy/CSS1&2 samples.

<sup>6</sup> Healthy carriers and those with incomplete penetrance are detectable.

<sup>7</sup> Patients with biallelic variants are distinguishable from those with monoallelic variants.

<sup>8</sup> This is a secondary epesignature; sample must also be positive for CHU\_BFL\_WHI.

<sup>9</sup> Only for variants within the amino acid range of 3400-3700.

<sup>10</sup> The range of validated coordinates is 1p36.33p36.32(1,019,753-2,867,961). CNVs overlapping or expanding this region may also be detected.

<sup>11</sup> The range of validated coordinates is 19p13.13p13.2(13,201,983-13,213,144). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. NFIX sequence variants have been shown to not match the epesignature.

<sup>12</sup> The range of validated coordinates is Xp11.22(53,559,057-53,654,518). CNVs overlapping or expanding this region may also be detected.

<sup>13</sup> This is a secondary epesignature; sample must also be positive for BAFopathy.

<sup>14</sup> Only for variants near c.2656. No separate epesignature due small cohort size however these samples cluster separately from other BAFopathy/CSS4 samples.

<sup>15</sup> Male CdLS5 patients (HDAC8 mutations) may be detected, but not confirmed in our experiments.

<sup>16</sup> Heterozygotes have been shown to not match the epesignature.

<sup>17</sup> Only for variants within the amino acid range of 960-1159.

<sup>18</sup> Reduced sensitivity against other Diamond-Blackfan anemia disorders may be observed.

<sup>19</sup> Patients with other FANC genes may be detected, but not confirmed in our experiments.

<sup>20</sup> Available as a targeted request only.

- 
- <sup>21</sup> GTPTS and SBBYSS are both caused by KAT6B mutations. We will report both regardless of which one is requested.
- <sup>22</sup> ADNP consists of two distinct epesignatures dependent on variant location. HVDAS\_T includes variants within the N- and C-terminus while HVDAS\_C includes variants within the central region (approximately c.2054-2340).
- <sup>23</sup> The range of validated coordinates is 5q35.2q35.3(175,839,681-176,904,798). CNVs overlapping or expanding this region may also be detected.
- <sup>24</sup> Sensitivity against other hereditary hypercholesterolemia disorders has not been evaluated. Both monoallelic and biallelic cases are detected.
- <sup>25</sup> ICF1 exhibits a unique epesignature while ICF 2, 3 and 4 exhibit a distinct, shared epesignature
- <sup>26</sup> This is a secondary epesignature; sample must also be positive for KBGS\_MRD23.
- <sup>27</sup> Heterozygotes have been shown to match the epesignature.
- <sup>28</sup> Heterozygotes have a distinct profile from hemizygotes.
- <sup>29</sup> This is a secondary signature; sample must also be positive for combined Kabuki signature.
- <sup>30</sup> XXX and YYY cases may also be detected.
- <sup>31</sup> Only for domain ID4. MKHK1/2 exhibit a shared ID4 domain epesignature and therefore cannot distinguish between MKHK1 and MKHK2. Other domains of MKHK1/2 are not available for assessment.
- <sup>32</sup> Healthy carriers and those with incomplete penetrance are detectable. Reduced sensitivity may be observed.
- <sup>33</sup> The range of validated coordinates is 4p16.3(1,832,733-1,975,031). CNVs overlapping or expanding this region may also be detected.
- <sup>34</sup> The range of validated coordinates is 22q13.3(49,238,268-50,248,907). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. *SHANK3* sequence variants have been shown to not match the epesignature.
- <sup>35</sup> The range of validated coordinates is 17p11.2(16,779,412-20,231,379). CNVs overlapping or expanding this region may also be detected. Reduced sensitivity may be observed.
- <sup>36</sup> Shared epesignatures between PRC2 complex syndromes WVS and COGIS. IMMAS (Imagawa-Matsumoto syndrome) cases with variants in SUZ12 have also been detected.
- <sup>37</sup> Includes cases with phenotypic presentation of OAV, OAVV, VACTERL and VATER.
- <sup>38</sup> This is a secondary signature; sample must also be positive for combined RSTS signature.
- <sup>39</sup> The range of validated coordinates is 17p11.2(17,322,913-18,515,769). CNVs overlapping or expanding this region may also be detected. Only for copy number variants. *RAI1* sequence variants have been shown to not match the epesignature.
- <sup>40</sup> The range of validated coordinates is 22q11.21(19,510,547-20,285,090). CNVs overlapping or expanding these regions may be detected.
- <sup>41</sup> The range of validated coordinates is 7q11.23(73,953,518-74,138,459). CNVs overlapping or expanding this region may also be detected.
- <sup>42</sup> CNVs overlapping or expanding 7q11.23 may also be detected.
- <sup>43</sup> The range of validated coordinates is 4p16.3(679,715-2,169,001). CNVs overlapping or expanding this region may also be detected. *NSD2* sequence variants have been shown to match the epesignature.